Antibody Drug Conjugates (ADC) Archives

Daiichi Sankyo Shuttering Plexxikon Site in Favor of ADCs

Antibody Drug Conjugates (ADC), Business, Daiichi Sankyo, Facilities/Sites/Manufacturing, Locations Closings, R&D, Subsidiaries, Therapeutics

As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device

Antibody Drug Conjugates (ADC), Business, Clinical Data, Clinical Trials, Companion Diagnostics, Diagnostic Tools, HER2 Mutations, Next-Generation Sequencing (NGS), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Partnerships, R&D

Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).

Magenta and Beam to Further Explore MGTA-117

Agreements, Antibody Drug Conjugates (ADC), Beta Thalassemia, Business, Clinical Trials, Collaborations, DNA, Hematopoietic Stem Cells, R&D, Sickle Cell Disease

Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.